Literature DB >> 18185987

Prevalence and correlates of previous hepatitis B vaccination and infection among young drug-users in New York City.

S Amesty1, D C Ompad, S Galea, C M Fuller, Y Wu, B Koblin, D Vlahov.   

Abstract

UNLABELLED: Hepatitis B (HBV) vaccination coverage remains low among drug users. In 1997, ACIP made hepatitis B vaccine available for persons aged 0-18 years and many states began requiring HBV vaccination for entry into middle school; these programs might affect HBV vaccination and infection rates in younger DUs. We were interested in determining correlates of immunization among younger (<25 years) and older (25 and older) DUs.
METHODS: A community-based sample of 1,211 heroin, crack, and cocaine users 18 or older was recruited from Harlem and the Bronx. We assessed previous HBV vaccination and infection and correlates using bivariate analyses.
RESULTS: The sample was predominantly male (74.0%), aged > or =25 years (67.1%) and Hispanic (59.9%). In terms of socioeconomic status, 57.1% had less than a high school education, 84.5% had been homeless in their lifetime, and 48.0% had an illegal main income source. Among 399 DUs younger than 25 years of age, 30% demonstrated serological evidence of previous vaccination, 49.9% were susceptible to HBV at baseline, and 20% showed evidence of infection. In our model, previous HBV infection and vaccination status were associated with being 22 years old or younger (AOR = 1.40 and 1.66). Compared to susceptible individuals, those vaccinated were significantly less likely to be born in other countries (AOR = 0.50). Among 812 DUs 25 and older, 10.6% demonstrated serological evidence of previous vaccination, 59.2% were susceptible to HBV at baseline, and 30.2% showed evidence of infection.
CONCLUSION: Existing interventions to increase HBV vaccination among adolescents should target high risk groups.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18185987     DOI: 10.1007/s10900-007-9082-4

Source DB:  PubMed          Journal:  J Community Health        ISSN: 0094-5145


  52 in total

1.  Providing hepatitis B vaccination to injection drug users: referral to health clinics vs on-site vaccination at a syringe exchange program.

Authors:  D C Des Jarlais; D G Fisher; J C Newman; B N Trubatch; M Yancovitz; D Paone; D Perlman
Journal:  Am J Public Health       Date:  2001-11       Impact factor: 9.308

2.  Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users.

Authors:  V Anna Gyarmathy; Alan Neaigus; Maureen Miller; Samuel R Friedman; Don C Des Jarlais
Journal:  J Acquir Immune Defic Syndr       Date:  2002-08-01       Impact factor: 3.731

3.  HBsAg positive adopted children as a cause of intrafamilial spread of hepatitis B.

Authors:  E Nordenfelt; E Dahlquist
Journal:  Scand J Infect Dis       Date:  1978

4.  Risk of hepatitis B infection among young injection drug users in San Francisco: opportunities for intervention.

Authors:  K H Seal; K C Ochoa; J A Hahn; J P Tulsky; B R Edlin; A R Moss
Journal:  West J Med       Date:  2000-01

5.  Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection.

Authors:  Irene Kuo; Susan G Sherman; David L Thomas; Steffanie A Strathdee
Journal:  Drug Alcohol Depend       Date:  2004-01-07       Impact factor: 4.492

6.  Risk factors for the transition from noninjection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users.

Authors:  E J van Ameijden; J A van den Hoek; C Hartgers; R A Coutinho
Journal:  Am J Epidemiol       Date:  1994-06-15       Impact factor: 4.897

7.  Occurrence of hepatitis A, B, and non-A/non-B in the United States. CDC sentinel county hepatitis study I.

Authors:  D P Francis; S C Hadler; T J Prendergast; E Peterson; M M Ginsberg; C Lookabaugh; J R Holmes; J E Maynard
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

8.  Incidence of hepatitis B virus infection in the United States, 1976-1994: estimates from the National Health and Nutrition Examination Surveys.

Authors:  P J Coleman; G M McQuillan; L A Moyer; S B Lambert; H S Margolis
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

9.  The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies.

Authors:  M J Alter; S C Hadler; H S Margolis; W J Alexander; P Y Hu; F N Judson; A Mares; J K Miller; L A Moyer
Journal:  JAMA       Date:  1990-03-02       Impact factor: 56.272

10.  Lack of transmission of HTLV-III/LAV infection to household contacts of patients with AIDS or AIDS-related complex with oral candidiasis.

Authors:  G H Friedland; B R Saltzman; M F Rogers; P A Kahl; M L Lesser; M M Mayers; R S Klein
Journal:  N Engl J Med       Date:  1986-02-06       Impact factor: 91.245

View more
  5 in total

1.  Implementation science and urban health research.

Authors:  Sebastian Bonner
Journal:  J Urban Health       Date:  2009-03       Impact factor: 3.671

2.  Housing instability among people who inject drugs: results from the Australian needle and syringe program survey.

Authors:  Libby Topp; Jenny Iversen; Eileen Baldry; Lisa Maher
Journal:  J Urban Health       Date:  2013-08       Impact factor: 3.671

3.  Predictors of HAV/HBV vaccination completion among methadone maintenance clients.

Authors:  Adeline Nyamathi; Karabi Sinha; Barbara Greengold; Allan Cohen; Mary Marfisee
Journal:  Res Nurs Health       Date:  2010-04       Impact factor: 2.228

4.  Correlates of susceptibility to hepatitis B among people who inject drugs in Sydney, Australia.

Authors:  Rachel M Deacon; Libby Topp; Handan Wand; Carolyn A Day; Craig Rodgers; Paul S Haber; Ingrid van Beek; Lisa Maher
Journal:  J Urban Health       Date:  2012-10       Impact factor: 3.671

5.  Let It "B"? The role of Hepatitis B universal vaccination among italian problematic drug users.

Authors:  Fabio Lugoboni; Raimondo Maria Pavarin; Chiara Resentera; Daniele Gambini
Journal:  Int J Environ Res Public Health       Date:  2015-04-13       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.